Skip to main content
. Author manuscript; available in PMC: 2009 Apr 20.
Published in final edited form as: Mol Cancer Ther. 2007 Mar;6(3):898–906. doi: 10.1158/1535-7163.MCT-06-0602

Figure 4. MCP110 effectively synergizes with paclitaxel to inhibit anchorage-dependent and independent growth of two distinct KSHV-GPCR transformed cell lines.

Figure 4

A. Proliferation assays were performed in NIH3T3-KSHV cells treated with paclitaxel alone (white), or in combination with MCP110 (black) or U0126 (light gray) at concentrations indicated. IC50 values determined for U0126 as monoagent was 20 μM.

B. Colony formation assays were performed in NIH3T3-KSHV cells treated with paclitaxel alone (white), or in combination with MCP110 (black), sorafenib (dark gray), or U0126 (light gray). IC50 values determined for sorafenib and U0126 used as monoagents were 15 and 20 μM, respectively.

C. Paclitaxel IC50 values were determined in proliferation assays performed in EC-vGPCR cells incubated with paclitaxel alone (white) or in combination with MCP110 (black), sorafenib (dark gray) or U0126 (gray) at 1 and 10 μM. IC50 values determined for sorafenib and U0126 used as monoagents were 15 and 54 μM, respectively. Note, EC-vGPCR cells do not form colonies in soft agar, so anchorage-independent growth could not be investigated.